Henry James International Management Inc. Invests $469,000 in RedHill Biopharma Ltd. (NASDAQ:RDHL)


Share on StockTwits

Henry James International Management Inc. acquired a new position in shares of RedHill Biopharma Ltd. (NASDAQ:RDHL) in the first quarter, HoldingsChannel.com reports. The firm acquired 64,043 shares of the biotechnology company’s stock, valued at approximately $469,000.

Several other institutional investors have also bought and sold shares of the company. Virtu Financial LLC boosted its stake in shares of RedHill Biopharma by 70.6% during the 4th quarter. Virtu Financial LLC now owns 30,187 shares of the biotechnology company’s stock worth $244,000 after buying an additional 12,490 shares during the last quarter. Steward Partners Investment Advisory LLC bought a new stake in shares of RedHill Biopharma in the 4th quarter valued at about $40,000. D.A. Davidson & CO. raised its holdings in shares of RedHill Biopharma by 54.4% in the 4th quarter. D.A. Davidson & CO. now owns 29,800 shares of the biotechnology company’s stock valued at $241,000 after purchasing an additional 10,500 shares during the period. Annandale Capital LLC bought a new stake in shares of RedHill Biopharma in the 4th quarter valued at about $352,000. Finally, BlackRock Inc. bought a new stake in shares of RedHill Biopharma in the 4th quarter valued at about $2,688,000. Institutional investors own 20.36% of the company’s stock.

Separately, Zacks Investment Research raised shares of RedHill Biopharma from a “sell” rating to a “hold” rating in a report on Friday, February 26th.

RedHill Biopharma stock traded down $0.10 during trading hours on Tuesday, hitting $6.68. The company had a trading volume of 6,321 shares, compared to its average volume of 552,476. The firm has a market cap of $309.92 million, a PE ratio of -3.90 and a beta of 1.71. The company has a debt-to-equity ratio of 2.79, a current ratio of 1.80 and a quick ratio of 1.64. RedHill Biopharma Ltd. has a one year low of $6.06 and a one year high of $11.52. The firm has a 50-day moving average of $7.53 and a 200 day moving average of $8.56.

RedHill Biopharma (NASDAQ:RDHL) last released its quarterly earnings results on Wednesday, March 17th. The biotechnology company reported ($0.70) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.36) by ($0.34). The company had revenue of $21.46 million during the quarter, compared to the consensus estimate of $26.72 million. RedHill Biopharma had a negative net margin of 142.81% and a negative return on equity of 152.19%. As a group, research analysts expect that RedHill Biopharma Ltd. will post -1.66 earnings per share for the current year.

RedHill Biopharma Profile

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focused on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults.

Recommended Story: Calculating net profit and net profit margin ratio

Want to see what other hedge funds are holding RDHL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for RedHill Biopharma Ltd. (NASDAQ:RDHL).

Institutional Ownership by Quarter for RedHill Biopharma (NASDAQ:RDHL)

Receive News & Ratings for RedHill Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RedHill Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.